Tirzepatide for Depression Patients: Evidence, Eligibility

Tirzepatide is not FDA approved for depression. It is approved for type 2 diabetes and heart risk. Some doctors prescribe it when one of those uses also applies. In SURMOUNT-1, people on Zepbound lost 20.9% of body weight on average, vs 3.1% on placebo.

Brands: Mounjaro and Zepbound
Best result (SURMOUNT-1): 20.9% weight loss

Zepbound in brief

How long it remains in your body

Its half-life runs 5 to 6 days: after 5.5 d half of it is gone, and after five half-lives (27.5 d) about 3% is left.

Body weight lost in the main trial

In SURMOUNT-1 over 72 weeks, body weight fell 20.9%, against 3.1% on placebo.

Cost as time goes on

Monthly prices in US dollars, including list price and self-pay offers, each taken from the maker's price page.

Sources: FDA label (DailyMed), Eli Lilly 1 2, cnbc.com.

Who qualifies?

Tirzepatide: who qualifies
Who sets the rule	Who qualifies
Mounjaro	Along with diet and exercise, it lowers blood sugar in adults and in children 10 and older with type 2 diabetes.
Mounjaro	Adults at high risk with type 2 diabetes see a lower chance of a heart attack, stroke, or a death linked to the heart.
Zepbound	With diet and activity, it helps adults with obesity, or those overweight with a weight-related condition, lose weight and keep it off long term.
Zepbound	In adults with obesity, it treats moderate to severe obstructive sleep apnea.
Medicare GLP-1 Bridge	BMI 35 or higher, no condition needed
Medicare GLP-1 Bridge	Heart failure, uncontrolled blood pressure, or CKD 3a+, and BMI of 30 or higher
Medicare GLP-1 Bridge	Prediabetes, PAD, or an earlier heart attack or stroke, plus BMI of 27 or higher
Typical commercial plan (Aetna policy)	BMI 30 or higher
Typical commercial plan (Aetna policy)	BMI 27 or higher with a weight-related condition
Typical commercial plan (Aetna policy)	a diet and activity program lasting 6 months comes first

Sources: FDA label (DailyMed) 1 2, medicare.gov 1 2, aetna.com.

Depression: what the trials showed

None of the trials enrolled people with depression only. Adults with obesity or overweight and no diabetes were studied, along with adults with obesity and no type 2 diabetes.

Tirzepatide trials in depression
Trial	Medicine	Who took part	Length	People	Main result	Comparison
SURMOUNT-1	Zepbound	Adults with obesity or overweight, without diabetes	72 weeks	2,539	20.9% weight loss	3.1% on placebo
SURMOUNT-5	Zepbound	Adults with obesity, without type 2 diabetes	72 weeks	751	20.2% weight loss	Not listed

Trial references: SURMOUNT-1 (FDA label (DailyMed)), SURMOUNT-5 (PubMed).

What is different for depression?

Label points on tirzepatide and depression
What changes	What the label says	Labels
Severe Gastrointestinal Adverse Reactions	Stomach and gut side effects are common, and some can be severe. Not recommended for people with severe gastroparesis.	All of them

According to FDA labels: FDA label (DailyMed).

These warnings come from the label: FDA label (DailyMed).

Coverage details for depression

Medicare Part D does not pay for a GLP-1 when it is used only for weight loss.

The Medicare GLP-1 Bridge list includes Zepbound at $50 a month for people who meet its rules.

Prior authorization is standard when Medicaid covers weight-loss GLP-1s.

Sources for this section: humana.com, CMS, KFF.

Alternatives for depression

GLP-1 medicines and depression
Medicine	For people with depression	How it is taken	Trial result
Mounjaro	Not a listed use	weekly injection	Not listed
Zepbound	Not a listed use	weekly injection	20.9% weight loss
Ozempic	Not a listed use	weekly injection	Not listed
Wegovy	Not a listed use	weekly injection or daily tablet	14.9% weight loss
Rybelsus	Not a listed use	daily tablet	Not listed
Foundayo	Not a listed use	daily tablet	11.1% weight loss
Trulicity	Not a listed use	weekly injection	Not listed
Saxenda	Not a listed use	daily injection	7.4% weight loss
Victoza	Not a listed use	daily injection	Not listed
Byetta	Not a listed use	twice-daily injection	Not listed